| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/16/2013 | WO2013067608A1 Immunomodulating compound for the treatment of cancerous tumours that are located in the internal and external epithelial tissue |
| 05/16/2013 | WO2013067581A1 Cancer treatment |
| 05/16/2013 | WO2013040504A3 Srpx for treatment of cancer |
| 05/16/2013 | WO2013027988A3 Recombinant adenovirus comprising trans-splicing ribozyme and cancer-treating gene, and use thereof |
| 05/16/2013 | WO2013024282A3 Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer |
| 05/16/2013 | US20130125259 Rna interference mediating small rna molecules |
| 05/16/2013 | US20130123255 Combination of a pi3k inhibitor and a mek inhibitor |
| 05/16/2013 | US20130123170 Growth Hormone Releasing Peptides |
| 05/16/2013 | US20130122110 Anti-human urothelial carcinoma of supercritical carbon dioxide extract of cinnamomum subavenium, and the preparation process and uses |
| 05/16/2013 | US20130122018 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 05/16/2013 | US20130121996 Novel Complex Mutations in the Epidermal Growth Factor Receptor Kinase Domain |
| 05/16/2013 | CA2855510A1 Nampt inhibitors |
| 05/16/2013 | CA2855362A1 Compounds for the modulation of beta-catenin expression and uses thereof |
| 05/16/2013 | CA2855358A1 Cyclin a1-targeted t-cell immunotherapy for cancer |
| 05/16/2013 | CA2855356A1 Biomarkers of response to proteasome inhibitors |
| 05/16/2013 | CA2855249A1 Treatment of ovarian cancer with benzylidenebenzohydrazides |
| 05/16/2013 | CA2855245A1 Treatment of ovarian cancer with 2-amino-4h-naphtho[1,2-b]pyran-3-carbonitriles |
| 05/16/2013 | CA2855243A1 Method of treating a proliferative disease |
| 05/16/2013 | CA2855211A1 N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| 05/16/2013 | CA2855180A1 Trolox derivative-modified fat-soluble anti-cancer pharmaceutical compounds, preparations, preparing methods and use thereof |
| 05/16/2013 | CA2855155A1 Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| 05/16/2013 | CA2854836A1 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction |
| 05/16/2013 | CA2854664A1 Method of quantifying cancer treatment |
| 05/16/2013 | CA2854622A1 Modulators of opioid receptors and methods of use thereof |
| 05/16/2013 | CA2854563A1 Provasopressin antagonists and uses thereof |
| 05/16/2013 | CA2854467A1 Antagonists for abnormal vasopressin v2 receptor and uses thereof |
| 05/16/2013 | CA2854336A1 Dual inhibitor of met and vegf for treating cancer |
| 05/16/2013 | CA2854329A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase |
| 05/16/2013 | CA2854186A1 Administration of a bis(thiohydrazide amide) compound for treating cancers |
| 05/16/2013 | CA2853836A1 Methods of inhibiting tumor growth by antagonizing il-6 receptor |
| 05/16/2013 | CA2853013A1 Composition for the photodynamic diagnosis and treatment of tumours |
| 05/16/2013 | CA2852991A1 Modulators of atp-binding cassette transporters |
| 05/16/2013 | CA2852127A1 Combination drug therapy for the treatment of solid tumors |
| 05/16/2013 | CA2850559A1 Combination therapy for ovarian cancer |
| 05/16/2013 | CA2849566A1 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| 05/15/2013 | EP2592093A1 Human c-fms antigen binding proteins |
| 05/15/2013 | EP2592086A1 Telomerase inhibitors and a method for the preparation thereof |
| 05/15/2013 | EP2592083A1 Fused quinazoline derivatives and uses thereof |
| 05/15/2013 | EP2592081A1 Tetrahydrocarboline derivative |
| 05/15/2013 | EP2592080A1 Crystal of fused pyridine compound salt |
| 05/15/2013 | EP2592073A2 Human protein tyrosine phosphatase inhibitors and their use |
| 05/15/2013 | EP2592072A2 Human protein tyrosine phosphatase inhibitors and their use |
| 05/15/2013 | EP2591805A1 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| 05/15/2013 | EP2591804A2 Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
| 05/15/2013 | EP2591803A1 Composition for the photodynamic diagnosis and treatment of tumours |
| 05/15/2013 | EP2591802A1 Vaccine compositions based on sticholysin encapsulated in liposomes |
| 05/15/2013 | EP2591799A1 Cancer peptide vaccine |
| 05/15/2013 | EP2591796A1 Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy |
| 05/15/2013 | EP2591777A2 L-NIL as inhibitor for regenerating the lung of a patient suffering from COPD |
| 05/15/2013 | EP2591775A1 Combinations comprising mtor inhibitors for treating cancer |
| 05/15/2013 | EP2591770A2 Compositions for siRNA delivery and methods of manufacturing and using same |
| 05/15/2013 | EP2591769A2 Compounds, compositions, kits and methods of use to topically treat acne and other skin conditions by administering a 19-nor containing vitamin D analog. |
| 05/15/2013 | EP2591106A1 Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway |
| 05/15/2013 | EP2591003A1 Cancer therapy using cldn6 target-directed antibodies in vivo |
| 05/15/2013 | EP2591002A2 Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr) |
| 05/15/2013 | EP2590999A1 Lipid-conjugated antibodies |
| 05/15/2013 | EP2590982A1 Protein kinase inhibitors and methods of treatment |
| 05/15/2013 | EP2590976A1 Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof |
| 05/15/2013 | EP2590975A1 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof |
| 05/15/2013 | EP2590966A1 Quinazoline compounds |
| 05/15/2013 | EP2590946A1 Bipyridyl derivatives useful for the treatment of kinase - induced diseases |
| 05/15/2013 | EP2590938A1 Novel sulfonamide compounds for inhibition of metastatic tumor growth |
| 05/15/2013 | EP2590681A1 Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| 05/15/2013 | EP2590680A1 Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| 05/15/2013 | EP2590678A1 Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| 05/15/2013 | EP2590677A1 Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
| 05/15/2013 | EP2590663A2 Use of parvovirus for eliminating cancer stem cells (cscs) |
| 05/15/2013 | EP2590654A1 Combinations of kinase inhibitors for the treatment of cancer |
| 05/15/2013 | EP2590648A2 Compounds for treatment of tumors bearing deregulated myc oncoproteins |
| 05/15/2013 | EP2590646A1 Method for inhibition of nf-kb gene expression |
| 05/15/2013 | EP2127652B1 Method for treating cancer using anticancer agent in combination |
| 05/15/2013 | CN103108882A Polycrystalline type object of CDDO BIEA and use thereof |
| 05/15/2013 | CN103108880A Osmium (ii) arene azo anti-cancer complexes |
| 05/15/2013 | CN103108873A Substituted imidazoquinoline derivatives as kinase inhibitors |
| 05/15/2013 | CN103108871A 17a-hydroxylase/c17,20-lyase inhibitors |
| 05/15/2013 | CN103108868A Furanyl compounds and the use thereof |
| 05/15/2013 | CN103108867A Oxadiazole compounds, their preparation and use |
| 05/15/2013 | CN103108649A Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
| 05/15/2013 | CN103108641A SDF-1 binding nucleic acids and the use thereof in cancer treatment |
| 05/15/2013 | CN103108636A Method for treating brain cancer |
| 05/15/2013 | CN103103264A Application of SMOC2 gene in preparation of medicine for detecting or treating endometrial cancer and ovarian cancer |
| 05/15/2013 | CN103103090A Silkworm chrysalis cordyceps wine and preparation method thereof |
| 05/15/2013 | CN103102416A Recombinant fusion protein of IL3 and Lidamycin, preparation method and application thereof |
| 05/15/2013 | CN103102412A Humanized anti-nasopharyngeal-cancer LMP2A extracellular region antibody Fab and application thereof |
| 05/15/2013 | CN103102399A Anti-tumor protein extracted from pholiota nameko and preparation method of antineoplastic protein |
| 05/15/2013 | CN103102392A N-terminal polypeptide of retinoic acid induced protein 16 and preparation method and application of antibody thereof |
| 05/15/2013 | CN103102385A Ardisia pusilla saponin derivants and application thereof |
| 05/15/2013 | CN103102376A Separation method for simultaneously separating cowherb seed flavonoid glycoside and cowherb seed total saponin |
| 05/15/2013 | CN103102360A Alanine copper complex as well as preparation method and application thereof |
| 05/15/2013 | CN103102359A Pyrimidine compounds and application thereof |
| 05/15/2013 | CN103102352A Tyrosine kinase inhibitor indolinone derivative |
| 05/15/2013 | CN103102349A Protein kinase inhibitor and composition and application thereof |
| 05/15/2013 | CN103102345A Aminoquinazoline derivative, salts thereof and application method |
| 05/15/2013 | CN103102344A Aminoquinazoline derivative, salts thereof and application method |
| 05/15/2013 | CN103102342A Aminoquinazoline derivative, salts thereof and application method |
| 05/15/2013 | CN103102339A Application of chalcone derivative in anticancer drugs |
| 05/15/2013 | CN103102336A Inula wissmannian extract and preparation thereof and application in preparation of antitumor drug |
| 05/15/2013 | CN103102332A Chalcone compound containing piperazine ring and preparation and application thereof |
| 05/15/2013 | CN103102331A Pharmaceutical application of chalcone compound containing piperazine ring |
| 05/15/2013 | CN103102315A Quinazoline arylurea and preparation method and application thereof |